The imSAVAR second stakeholder workshop was held on the fourth of November 2020. There were 51 attendees. The Consortium decided to keep this workshop internal to be able to share more details and allow an open discussion. The focus was on the Checkpoint Inhibitor Mechanism of action.
The workshop began with a presentation of the work that has been done to complete a immune related adverse outcome pathway for checkpoint inhibitors. The regulatory perspective was then provided by one of our regulatory experts. The workshop went really well with the result to move forward with the different irAOPS with the development of more case studies, engagement of industry partners and evolution of the organ on a chip models.
The third and then again public stakeholder workshop will take place on 12 and 13 April 2021.